(Q37872670)

24 August 2017

1 reference

title

Mechanisms of mTOR inhibitor resistance in cancer therapy (English)

1 reference

24 August 2017

Jennifer S Carew

1

1 reference

24 August 2017

Kevin R Kelly

series ordinal

2

1 reference

24 August 2017

Steffan T Nawrocki

series ordinal

3

1 reference

24 August 2017

publication date

9 March 2011

1 reference

24 August 2017

1 reference

24 August 2017

volume

6

1 reference

24 August 2017

issue

1

1 reference

24 August 2017

page(s)

17-27

1 reference

https://scigraph.springernature.com/pub.10.1007/s11523-011-0167-8

24 August 2017

exact match

0 references

cites work

Two TOR complexes, only one of which is rapamycin sensitive, have distinct roles in cell growth control

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0167-8

Raptor, a binding partner of target of rapamycin (TOR), mediates TOR action

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0167-8

mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0167-8

DEPTOR is an mTOR inhibitor frequently overexpressed in multiple myeloma cells and required for their survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0167-8

PRAS40 is an insulin-regulated inhibitor of the mTORC1 protein kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0167-8

Insulin signalling to mTOR mediated by the Akt/PKB substrate PRAS40

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0167-8

Structure of the FKBP12-rapamycin complex interacting with the binding domain of human FRAP

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0167-8

Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0167-8

Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0167-8

Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0167-8

Rheb binds and regulates the mTOR kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0167-8

Rapamycin suppresses 5'TOP mRNA translation through inhibition of p70s6k.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0167-8

mTOR and S6K1 mediate assembly of the translation preinitiation complex through dynamic protein interchange and ordered phosphorylation events

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0167-8

Phosphorylation of eucaryotic translation initiation factor 4B Ser422 is modulated by S6 kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0167-8

Current development of mTOR inhibitors as anticancer agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0167-8

The TOR pathway: a target for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0167-8

mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0167-8

A Tumor Suppressing Duo: TGFβ and Activin Modulate a Similar Transcriptome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0167-8

Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0167-8

Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0167-8

Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0167-8

An inhibitor of mTOR reduces neoplasia and normalizes p70/S6 kinase activity in Pten+/- mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0167-8

Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0167-8

CCI-779 in metastatic melanoma: a phase II trial of the California Cancer Consortium

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0167-8

Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0167-8

The von Hippel-Lindau tumor suppressor protein and clear cell renal carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0167-8

Ubiquitination of hypoxia-inducible factor requires direct binding to the beta-domain of the von Hippel-Lindau protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0167-8

Vorinostat enhances the activity of temsirolimus in renal cell carcinoma through suppression of survivin levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0167-8

Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0167-8

Dominant mutations confer resistance to the immunosuppressant, rapamycin, in variants of a T cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0167-8

FK506 binding protein 12 mediates sensitivity to both FK506 and rapamycin in murine mast cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0167-8

TOR mutations confer rapamycin resistance by preventing interaction with FKBP12-rapamycin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0167-8

Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0167-8

An ATP-competitive mammalian target of rapamycin inhibitor reveals rapamycin-resistant functions of mTORC1

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0167-8

Biochemical, cellular, and in vivo activity of novel ATP-competitive and selective inhibitors of the mammalian target of rapamycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0167-8

Dual inhibition of PI3K and mTOR inhibits autocrine and paracrine proliferative loops in PI3K/Akt/mTOR-addicted lymphomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0167-8

Ablation of PI3K blocks BCR-ABL leukemogenesis in mice, and a dual PI3K/mTOR inhibitor prevents expansion of human BCR-ABL+ leukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0167-8

Mammalian target of rapamycin inhibitors activate the AKT kinase in multiple myeloma cells by up-regulating the insulin-like growth factor receptor/insulin receptor substrate-1/phosphatidylinositol 3-kinase cascade.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0167-8

Mammalian target of rapamycin (mTOR) inhibition activates phosphatidylinositol 3-kinase/Akt by up-regulating insulin-like growth factor-1 receptor signaling in acute myeloid leukemia: rationale for therapeutic inhibition of both pathways.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0167-8

Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0167-8

Inhibition of histone deacetylase overcomes rapamycin-mediated resistance in diffuse large B-cell lymphoma by inhibiting Akt signaling through mTORC2

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0167-8

Activity of the novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 against T-cell acute lymphoblastic leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0167-8

The efficacy of the novel dual PI3-kinase/mTOR inhibitor NVP-BEZ235 compared with rapamycin in renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0167-8

Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0167-8

Antimyeloma activity of the orally bioavailable dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0167-8

Rapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0167-8

Inhibition of mammalian target of rapamycin induces phosphatidylinositol 3-kinase-dependent and Mnk-mediated eukaryotic translation initiation factor 4E phosphorylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0167-8

Effective and selective targeting of leukemia cells using a TORC1/2 kinase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0167-8

Pim and Akt oncogenes are independent regulators of hematopoietic cell growth and survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0167-8

PIM1 protein kinase regulates PRAS40 phosphorylation and mTOR activity in FDCP1 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0167-8

Novel benzylidene-thiazolidine-2,4-diones inhibit Pim protein kinase activity and induce cell cycle arrest in leukemia and prostate cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0167-8

The Pim kinases control rapamycin-resistant T cell survival and activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0167-8

B55β-associated PP2A complex controls PDK1-directed myc signaling and modulates rapamycin sensitivity in colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0167-8

Target of rapamycin (TOR): balancing the opposing forces of protein synthesis and degradation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0167-8

B cell receptor-associated protein alpha4 displays rapamycin-sensitive binding directly to the catalytic subunit of protein phosphatase 2A

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0167-8

4E-binding proteins, the suppressors of eukaryotic initiation factor 4E, are down-regulated in cells with acquired or intrinsic resistance to rapamycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0167-8

Targeting the eukaryotic translation initiation factor 4E for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0167-8

Rapamycin resistance tied to defective regulation of p27Kip1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0167-8

Superoxide anions regulate TORC1 and its ability to bind Fpr1:rapamycin complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0167-8

Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0167-8

Sustained activation of the JNK cascade and rapamycin-induced apoptosis are suppressed by p53/p21(Cip1)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0167-8

IAPs: from caspase inhibitors to modulators of NF-kappaB, inflammation and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0167-8

Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0167-8

Modulating autophagy for therapeutic benefit

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0167-8

RAD001 (Everolimus) induces autophagy in acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0167-8

Critical roles for mTORC2- and rapamycin-insensitive mTORC1-complexes in growth and survival of BCR-ABL-expressing leukemic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0167-8

Active cell death induced by the anti-estrogens tamoxifen and ICI 164 384 in human mammary carcinoma cells (MCF-7) in culture: the role of autophagy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0167-8

Role of autophagy in temozolomide-induced cytotoxicity for malignant glioma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0167-8

Apoptotic and autophagic cell death induced by histone deacetylase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0167-8

Proteasome inhibitors activate autophagy as a cytoprotective response in human prostate cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0167-8

Autophagy inhibition enhances therapy-induced apoptosis in a Myc-induced model of lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0167-8

Targeting autophagy potentiates tyrosine kinase inhibitor-induced cell death in Philadelphia chromosome-positive cells, including primary CML stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0167-8

Autophagy inhibition enhances vorinostat-induced apoptosis via ubiquitinated protein accumulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0167-8

Targeting autophagy augments the anticancer activity of the histone deacetylase inhibitor SAHA to overcome Bcr-Abl-mediated drug resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0167-8

Targeting TORC2 in multiple myeloma with a new mTOR kinase inhibitor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0167-8

Genetic dissection of the oncogenic mTOR pathway reveals druggable addiction to translational control via 4EBP-eIF4E

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0167-8

A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0167-8

NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0167-8

Dual inhibition of akt/mammalian target of rapamycin pathway by nanoparticle albumin-bound-rapamycin and perifosine induces antitumor activity in multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0167-8

mTORC1 promotes survival through translational control of Mcl-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0167-8

Inhibition of mTOR restores cisplatin sensitivity through down-regulation of growth and anti-apoptotic proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0167-8

Gene expression-based chemical genomics identifies rapamycin as a modulator of MCL1 and glucocorticoid resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0167-8

AKT/mTOR pathway activation and BCL-2 family proteins modulate the sensitivity of human small cell lung cancer cells to RAD001.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0167-8

Determinants of sensitivity and resistance to rapamycin-chemotherapy drug combinations in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0167-8

ABT-263 and rapamycin act cooperatively to kill lymphoma cells in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0167-8

Combined Bcl-2/mammalian target of rapamycin inhibition leads to enhanced radiosensitization via induction of apoptosis and autophagy in non-small cell lung tumor xenograft model

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0167-8

Sorafenib and rapamycin induce growth suppression in mouse models of hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0167-8

Rapamycin-induced endothelial cell death and tumor vessel thrombosis potentiate cytotoxic therapy against pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0167-8

Antiangiogenic potential of the Mammalian target of rapamycin inhibitor temsirolimus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0167-8

AKT activity regulates the ability of mTOR inhibitors to prevent angiogenesis and VEGF expression in multiple myeloma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0167-8

Pathological angiogenesis is induced by sustained Akt signaling and inhibited by rapamycin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0167-8

Effect of rapamycin alone and in combination with antiangiogenesis therapy in an orthotopic model of human pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0167-8

Survival benefit with proapoptotic molecular and pathologic responses from dual targeting of mammalian target of rapamycin and epidermal growth factor receptor in a preclinical model of pancreatic neuroendocrine carcinogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0167-8

Phase II trial of bevacizumab and everolimus in patients with advanced renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0167-8

Combined targeting of the VEGFr/EGFr and the mammalian target of rapamycin (mTOR) signaling pathway delays cell cycle progression and alters adhesion behavior of prostate carcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0167-8

Effects of combined inhibition of MEK and mTOR on downstream signaling and tumor growth in pancreatic cancer xenograft models

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0167-8

Combination strategy targeting the hypoxia inducible factor-1 alpha with mammalian target of rapamycin and histone deacetylase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0167-8

Alternative cell death mechanisms in development and beyond

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0167-8

The molecular target of rapamycin (mTOR) as a therapeutic target against cancer

21 January 2018

1 reference

12 December 2020

Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer

1 reference

12 December 2020

Rapamycin and UCN-01 synergistically induce apoptosis in human leukemia cells through a process that is regulated by the Raf-1/MEK/ERK, Akt, and JNK signal transduction pathways

1 reference

12 December 2020

A novel response of cancer cells to radiation involves autophagy and formation of acidic vesicles

1 reference

12 December 2020

The dual PI3K/mTOR inhibitor PI-103 promotes immunosuppression, in vivo tumor growth and increases survival of sorafenib-treated melanoma cells.

1 reference

12 December 2020

Induction of autophagic cell death in malignant glioma cells by arsenic trioxide.

1 reference

12 December 2020

mTOR-dependent regulation of PHLPP expression controls the rapamycin sensitivity in cancer cells

1 reference

12 December 2020

Lucanthone is a novel inhibitor of autophagy that induces cathepsin D-mediated apoptosis

1 reference

12 December 2020

Rapamycin enhances apoptosis and increases sensitivity to cisplatin in vitro

1 reference

12 December 2020

Targeting AKT/mTOR and ERK MAPK signaling inhibits hormone-refractory prostate cancer in a preclinical mouse model

1 reference

12 December 2020

Synergistic augmentation of rapamycin-induced autophagy in malignant glioma cells by phosphatidylinositol 3-kinase/protein kinase B inhibitors.

1 reference

12 December 2020

Rapamycin selectively inhibits the growth of childhood rhabdomyosarcoma cells through inhibition of signaling via the type I insulin-like growth factor receptor.

1 reference

12 December 2020

Enforced expression of the Mr 33,000 Pim-1 kinase enhances factor-independent survival and inhibits apoptosis in murine myeloid cells

1 reference

12 December 2020

Rapamycin causes poorly reversible inhibition of mTOR and induces p53-independent apoptosis in human rhabdomyosarcoma cells.

1 reference

12 December 2020

The Pim protein kinases regulate energy metabolism and cell growth

1 reference

12 December 2020

10.1007/S11523-011-0167-8

Identifiers

DOI

1 reference

24 August 2017

1 reference